GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2cureX AB (OSTO:2CUREX) » Definitions » EV-to-EBITDA

2cureX AB (OSTO:2CUREX) EV-to-EBITDA : 0.39 (As of May. 21, 2024)


View and export this data going back to 2017. Start your Free Trial

What is 2cureX AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, 2cureX AB's enterprise value is kr-11.91 Mil. 2cureX AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was kr-30.77 Mil. Therefore, 2cureX AB's EV-to-EBITDA for today is 0.39.

The historical rank and industry rank for 2cureX AB's EV-to-EBITDA or its related term are showing as below:

OSTO:2CUREX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.59   Med: -15.88   Max: 0.42
Current: 0.39

During the past 8 years, the highest EV-to-EBITDA of 2cureX AB was 0.42. The lowest was -35.59. And the median was -15.88.

OSTO:2CUREX's EV-to-EBITDA is ranked better than
81.44% of 458 companies
in the Biotechnology industry
Industry Median: 10.31 vs OSTO:2CUREX: 0.39

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), 2cureX AB's stock price is kr0.352. 2cureX AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was kr-1.874. Therefore, 2cureX AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


2cureX AB EV-to-EBITDA Historical Data

The historical data trend for 2cureX AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2cureX AB EV-to-EBITDA Chart

2cureX AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial -15.88 -15.38 -23.52 -10.02 -3.35

2cureX AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.96 -3.35 -2.80 -1.58 -1.27

Competitive Comparison of 2cureX AB's EV-to-EBITDA

For the Biotechnology subindustry, 2cureX AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2cureX AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2cureX AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 2cureX AB's EV-to-EBITDA falls into.



2cureX AB EV-to-EBITDA Calculation

2cureX AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-11.908/-30.769
=0.39

2cureX AB's current Enterprise Value is kr-11.91 Mil.
2cureX AB's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-30.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


2cureX AB  (OSTO:2CUREX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

2cureX AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.352/-1.874
=At Loss

2cureX AB's share price for today is kr0.352.
2cureX AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.874.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


2cureX AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 2cureX AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


2cureX AB (OSTO:2CUREX) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Copenhagen, DNK, DK-2100
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.

2cureX AB (OSTO:2CUREX) Headlines

No Headlines